Open Access<p>Hypertension and Ischemic Stroke After Aflibercept for Retinopathy of Prematurity</p>
Author(s) -
Fatemeh Bazvand,
Elias Khalili Pour,
Golnaz Gharehbaghi,
Hooshang Faghihi,
Ali Khodabandeh,
Mohammadreza Mehrabi Bahar,
Hamid Riazi-Esfahani
Publication year - 2020
Publication title -
international medical case reports journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.198
H-Index - 11
ISSN - 1179-142X
DOI - 10.2147/imcrj.s258881
Subject(s) - aflibercept , medicine , retinopathy of prematurity , stroke (engine) , adverse effect , ophthalmology , pediatrics , anesthesia , bevacizumab , gestational age , pregnancy , chemotherapy , mechanical engineering , biology , engineering , genetics
Retinopathy of prematurity is the leading cause of preterm infants' blindness. The preferred method for the management of aggressive posterior ROP is the anti-vascular endothelial growth factor (anti-VEGF). However, systemic and ocular adverse effects of anti-VEGF drugs remain a concern.